F
Financials.page
Company Fundamentals
Workspace
OverviewhomeCompaniesdirectoryAPI & MCPdevelopers
Company financial data, refreshed daily. Not investment advice.
Financials.page — company financial data, refreshed daily. Not investment advice. Legal & terms
Annual figures as reported in 10-K / 20-F / 40-F filings.
LSBCF · CIK 0001946399

LakeShore Biopharma Co., Ltd

Annual figures as reported, FY2020–FY2025. Ratios and growth rates derived on-page.

LSBCF logo
Pharmaceutical Preparations
Company profile
OTC · LSBCFHQ Daxing District, Beijing, ChinaIncorporated in E9Fiscal year ends Mar 31Non-accelerated filer Emerging growth companyReports in CNY
Revenue
CN¥615.0M
▲ +7.2% vs FY2024
Net income
−CN¥100.0M
▲ +76.9% vs FY2024
Free cash flow
−CN¥133.7M
▲ +60.6% vs FY2024
Diluted EPS
−CN¥5.22
▲ +87.1% vs FY2024

Revenue

Annual, as reported

0200M400M600M’21’22’23’24’25CN¥615.0M

Net income

Losses shown in terracotta

−400M−200M0’21’22’23’24’25−CN¥100.0M

Profitability & returns

quality of earnings

Margins

Share of revenue kept at each line

-50%0%50%’21’22’23’24’25
Gross marginOperating marginNet margin

Returns on capital

Net income vs year-end equity and assets

-60%-40%-20%0%’22’23’24’25
Return on equityReturn on assets

Cash flow

cash generation

Free cash flow

Operating cash flow less capital expenditure

−400M−200M0’21’22’23’24’25−CN¥133.7M

Operating cash flow

Net cash from operations

−200M−100M0’21’22’23’24’25−CN¥121.0M

Shareholder returns

capital allocation

Diluted shares outstanding

Falling count means buybacks outpace dilution

05M10M15M’21’22’23’24’2519M

Balance sheet

financial position

Stockholders’ equity

At fiscal year end

−500M0500M’20’21’22’23’24’25CN¥499.8M

Net debt

Long-term debt less cash — negative means net cash

−100M−50M0’22’23’24’25−CN¥84.0M

Growth rates

compounding, annualized
Revenue CAGR
+6.9%
3y

Key ratios

derived per fiscal year
Fiscal yearGross marginOp. marginNet marginFCF marginROEROACurrent ratioDebt / equity
FY202582.5%−14.0%−16.3%−21.7%−20.0%−7.3%1.02×0.05×
FY202479.5%−77.7%−75.6%−59.2%−74.1%−28.6%1.13×0.17×
FY202377.7%−20.3%−21.2%−34.2%−20.0%−8.5%1.57×0.40×
FY202276.7%−23.7%−21.1%−93.2%—−7.4%1.61×—
FY202176.8%−49.0%−74.6%−136.8%————
FY2020————————

Annual figures

as reported
Fiscal yearRevenueGross profitOp. incomeNet incomeDiluted EPSOp. cash flowCapexTotal assetsLiabilitiesEquityCashLT debt
FY2025CN¥615.0MCN¥507.2M−CN¥86.3M−CN¥100.0M−CN¥5.22−CN¥121.0MCN¥12.7MCN¥1.4BCN¥867.9MCN¥499.8MCN¥107.5MCN¥23.5M
FY2024CN¥573.4MCN¥455.7M−CN¥445.8M−CN¥433.5M−CN¥40.54−CN¥295.2MCN¥44.3MCN¥1.5BCN¥927.8MCN¥585.2MCN¥246.6MCN¥99.0M
FY2023CN¥687.2MCN¥533.8M−CN¥139.4M−CN¥145.5M−CN¥23.55−CN¥182.5MCN¥52.8MCN¥1.7BCN¥991.3MCN¥728.5MCN¥370.4MCN¥293.8M
FY2022CN¥502.9MCN¥385.9M−CN¥119.0M−CN¥106.0M−CN¥17.10−CN¥173.5MCN¥295.3MCN¥1.4BCN¥770.5M−CN¥699.0MCN¥271.1MCN¥253.9M
FY2021CN¥257.0MCN¥197.4M−CN¥125.8M−CN¥191.8M−CN¥46.50−CN¥246.6MCN¥104.9M——−CN¥508.9MCN¥390.5M—
FY2020—————————−CN¥847.3MCN¥2.1M—

Latest filings

the most recent regulatory filings
SCHEDULE 13D/ASEC filing2026-06-25 ↗15-12GSEC filing2026-06-24 ↗S-8 POSPOST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-82026-06-24 ↗S-8 POSPOST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-82026-06-24 ↗SC 13E3/AAMENDMENT NO. 8 TO SCHEDULE 13E-32026-06-24 ↗6-KREPORT OF FOREIGN PRIVATE ISSUER2026-06-24 ↗6-KREPORT OF FOREIGN PRIVATE ISSUER2026-06-22 ↗6-KREPORT OF FOREIGN PRIVATE ISSUER2026-05-28 ↗SC 13E3/AAMENDMENT NO. 7 TO SCHEDULE 13E-32026-05-28 ↗SC 13E3/AAMENDMENT NO. 6 TO SCHEDULE 13E-32026-05-08 ↗

Company logos by Elbstream and unavatar.

All third-party trademarks, service marks, logos, and brand names used on this site are the property of their respective owners. The use of these logos is for identification and illustrative purposes only and does not imply any affiliation, sponsorship, or endorsement by the respective owners.